A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
Recruiting
This study is a multi-center, double-blind, placebo-controlled, randomized Phase 3 trial to assess the safety and efficacy of AXS-12 in narcoleptic subjects with cataplexy and excessive daytime sleepiness (EDS).
Gender:
All
Ages:
Between 15 years and 75 years
Trial Updated:
03/03/2023
Locations: Clinical Research Site, West Long Branch, New Jersey
Conditions: Narcolepsy, Cataplexy, Excessive Daytime Sleepiness